New York, New York, September 14, 2022 –(PR.com)– BDA Partners is pleased to announce that Navis Capital (“Navis”), advised by William Blair and BDA Partners, has agreed to sell 100% of B Medical Systems (“B Med”) to Azenta, Inc (“Azenta “) for sale. ), a leading provider of cold chain sample management solutions and genomics services to leading pharmaceutical, biotechnology, academic and healthcare institutions worldwide. The transaction values B Med at an enterprise value of up to EUR 460 million and is expected to close in October 2022.
B Med is the global leader in sustainable medical cold chain solutions with a presence in over 150 countries. As the world’s largest vaccine cold chain provider, B Med ensures the safe and reliable storage and shipment of temperature-sensitive vaccines to a significant portion of the world’s population, particularly in emerging markets in Asia, Latin America and Africa where power grids are unreliable and in places non-existent.
Nicholas Bloy, Managing Partner at Navis, commented: “B Med is an interesting case study that illustrates the successful execution of a product development strategy focused solely on delivering medical devices and data that help organizations around the world save millions of lives rescue. We wish our trusted friends and partners at B Med well as they embark on the next phase of their growth journey with Azenta.”
Luc Provost, CEO of B Med, commented: “We are proud to be the partner of choice for countries that help save lives through the safe and reliable delivery of vaccines, blood and medicines. Over the past seven years we have created an incredible growth platform that will lead to several new initiatives over the next few years. We are excited to be part of the Azenta family and we know that we will create significant value – both financially and socially – as we embark on a new journey together.”
Andrew Huntley, Managing Partner and Global Head of Healthcare, BDA Partners, said: “We have…
